Senolytics in 2026: Clinical Trials, Failures, and What Longevity Clinics Are Actually Offering

Senolytics — therapies designed to selectively eliminate senescent cells — were once the darling of longevity medicine. The logic was elegant: senescent cells accumulate with age, secrete pro-inflammatory factors (the senescence-associated secretory phenotype, or SASP), and drive tissue dysfunction. Remove them, and you restore youthful function.

The 2011 Baker et al. study in mice seemed to prove the concept: clearing senescent cells extended healthspan and delayed age-related pathologies.¹ By 2020, dozens of biotech companies had entered the race, venture capital poured in, and longevity clinics began offering off-label senolytic protocols.

Then came the clinical reality check.

In 2023, Unity Biotechnology’s lead senolytic candidate UBX1325 — a BCL-xL inhibitor targeting senescent cells in the eye — failed to meet its primary endpoint in a Phase 2 trial for wet age-related macular degeneration (AMD). The drug didn’t achieve non-inferiority to Regeneron’s Eylea, in part because the control arm showed an unexpectedly strong 3.5-letter visual acuity gain.²³ Unity’s stock nearly halved.

More recently, in March 2025, UBX1325 failed again — this time in diabetic macular edema (DME). Despite showing some vision improvements, the drug missed its primary analysis endpoint in the ASPIRE trial.⁴ Unity extended the trial to 36 weeks and increased enrollment, signaling continued belief in the mechanism, but the setbacks have been sobering for the field.

As of March 2026, no senolytic drug has been approved by the FDA. Yet the science remains compelling, next-generation approaches are entering the clinic, and longevity clinics continue to offer senolytic protocols — mostly centered on the repurposed drug combination dasatinib + quercetin (D+Q).

Here’s the real state of senolytics in 2026: what works, what failed, what’s coming, and what you can actually get at a longevity clinic today.

What Are Senolytics? The Biology Behind the Hype

Cellular senescence is a state in which cells stop dividing but resist programmed cell death (apoptosis). It’s a double-edged sword.

The good: Senescence plays essential roles in:

Development — orchestrating tissue remodeling during embryogenesis
Wound healing — preventing fibrosis and promoting tissue repair
Cancer suppression — halting the replication of damaged or pre-cancerous cells⁵

The bad: As we age, senescent cells accumulate because:

Immune surveillance declines (fewer senescent cells are cleared)
Chronic stressors (oxidative damage, mitochondrial dysfunction, DNA damage) push more cells into senescence
Senescent cells secrete the SASP — a cocktail of pro-inflammatory cytokines, matrix metalloproteinases, and growth factors that create a toxic microenvironment, “infecting” neighboring cells and driving chronic inflammation, fibrosis, and stem cell dysfunction.⁶

The SASP includes:

IL-6, IL-8 — pro-inflammatory cytokines
MMP-3, MMP-9 — enzymes that degrade extracellular matrix
VEGF — promotes angiogenesis, potentially feeding tumors
TGF-β — drives fibrosis

By age 60, an estimated 10-15% of cells in certain tissues are senescent — enough to cause measurable functional decline.⁷

The promise of senolytics: Drugs that selectively kill senescent cells could reverse this decline without harming healthy cells.

The challenge? Senescent cells are heterogeneous. They express different markers depending on tissue type, age, and the stressor that induced senescence. A “one-size-fits-all” senolytic may not exist.

The Hype Cycle: From Baker 2011 to Clinical Setbacks

2011: The Breakthrough

Baker et al. engineered INK-ATTAC mice — a model in which senescent cells expressing p16^INK4a^ could be selectively eliminated via drug-induced apoptosis. When the team cleared senescent cells in aged mice, they saw:

Delayed onset of age-related pathologies (cataracts, muscle loss, fat tissue dysfunction)
Extended median lifespan by 20-30% in progeroid mice
Improved healthspan metrics across multiple organ systems¹

This was the proof-of-concept that launched the field.

2015-2020: The Gold Rush

Dozens of biotech companies launched senolytic programs:

Unity Biotechnology (UBX1325, UBX0101) — BCL-xL inhibitors
Oisín Biotechnologies — gene therapy targeting p16+ cells
Senolytic Therapeutics (now part of Cyclerion) — p16/p21 pathway modulators

Dasatinib + quercetin (D+Q), a repurposed cancer drug + natural flavonoid combo, emerged as the first clinically tested senolytic in humans. Mayo Clinic researchers showed it could reduce senescent cell burden in patients with diabetic kidney disease.⁸

Longevity clinics began offering D+Q protocols off-label, often without formal trials.

2023-2025: The Reality Check

Unity’s failures in AMD and DME were wake-up calls. The field realized:

Biomarkers are inadequate — We lack standardized ways to measure senescent cell clearance and link it to clinical outcomes
Senescence is heterogeneous — What works in fibroblasts may not work in endothelial cells, immune cells, or neurons
Safety windows are narrow — Many senolytics are repurposed cancer drugs (BCL-2/BCL-xL inhibitors, tyrosine kinase inhibitors) with off-target toxicity

As Adam Freund, CEO of Arda Therapeutics, put it in a recent expert roundup:

“The senescence field is built on a paradox: it is simultaneously too narrow in its foundational models and too inclusive in its subsequent definitions. Single-cell data show that traditional in vitro models of senescence have little overlap with cell states found in human disease, and the classic markers of senescence are expressed by a multitude of normal cell types.”⁹

Translation: We’ve been aiming at the wrong target with the wrong tools.

Next-Generation Senolytics: The Companies to Watch in 2026

Despite setbacks, several biotech companies are advancing novel senolytic and senomorphic approaches into the clinic. Here’s who’s leading the charge:

1. Rubedo Life Sciences — GPX4 Modulation

Approach: Rubedo developed RLS-1496, a GPX4-modulating senotherapeutic designed to exploit the unique vulnerabilities of senescent cells.

Platform: ALEMBIC, an AI-driven multi-omics platform that resolves cellular heterogeneity at high resolution, allowed Rubedo to identify GPX4-related biology as a critical dependency in certain senescent states.

Status: RLS-1496 is in Phase 1/2 clinical trials in the U.S. and Europe, targeting dermatology and fibrotic diseases. Rubedo is using a “basket trial” design — testing the drug in both chronic skin lesions and healthy skin to evaluate effects on disease and skin aging simultaneously.⁹

CEO Marco Quarta:

“This is precision senotherapeutics: identifying functional dependencies and designing selective therapies matched to specific disease biology.”⁹

2. SENISCA — Single-Gene Reprogramming

Approach: SENISCA uses a unique oligonucleotide-based single-gene reprogramming approach that resets cells’ ability to properly regulate senescence-related genes — not by overexpressing or knocking down genes, but by restoring their natural, endogenously regulated expression.

Platform: Developed by Prof. Lorna Harries (University of Exeter), this approach is distinct from conventional epigenetic reprogramming.

Status: Lead asset is being developed for idiopathic pulmonary fibrosis (IPF), a rare disease eligible for orphan drug designation. The technology has also been validated in a global cosmeceutical partnership for skin health applications, providing human in vivo proof of concept.⁹

Prof. Harries:

“We have a unique approach that works with the cells’ own biology to restore their natural gene expression. It’s not senolysis — it’s cellular reprogramming while leaving the tissue microenvironment intact.”⁹

3. Deciduous Therapeutics — Immune Restoration

Approach: Instead of killing senescent cells directly, Deciduous restores the function of invariant Natural Killer T (iNKT) cells, the immune cells responsible for clearing senescent cells. Their lead asset is a small molecule that specifically restores iNKT function, leading to single-dose efficacy in metabolic and fibrotic diseases.

Rationale: An effective immune system quickly recognizes and ablates senescent cells. But iNKT function declines with age. Restoring it reactivates endogenous senescent cell clearance.

Safety profile: No safety issues observed even at 30x the efficacious dose — a stark contrast to repurposed cancer drugs with narrow therapeutic windows.⁹

CEO Robin Mansukhani:

“Off-target safety issues have been a primary bottleneck in the senescence field. Our approach is to restore endogenous immune pathways.”⁹

4. Arda Therapeutics — Disease-First Cell Depletion

Approach: Arda is disease-first, not senescence-first. Instead of searching for cells expressing senescence markers, Arda’s platform identifies and targets disease-driving cell states — regardless of their relationship to traditional senescence.

Platform: High-resolution discovery engine combining multi-modal single-cell transcriptomics, human genetics, and disease biomarkers to pinpoint pathogenic cell populations. Once identified, Arda designs therapies for selective, sensitive depletion of target cells while sparing healthy tissue.

Status: Pursuing precision cell depletion across inflammatory and immunological indications, with an initial focus on fibrosis.⁹

CEO Adam Freund:

“Most companies in the senescence space start with senescent cell markers and then search for diseases. We start with the disease, identify the pathogenic cell state, and eliminate it — whether or not it fits the traditional senescence definition.”⁹

What Longevity Clinics Are Actually Offering in 2026

While next-generation senolytics are still in clinical trials, longevity clinics are offering senolytic protocols today — primarily centered on dasatinib + quercetin (D+Q).

The conversation is increasingly mainstream. As longevity journalist Elena put it after a recent Huberman Lab interview with Stanford’s Tony Wyss-Coray: “There is still no intervention that has been tested and confirmed to extend human lifespan in healthy people. Not supplements. Not optimization stacks.” That sobriety applies directly to senolytics — promising mechanism, unfinished evidence.

Dasatinib + Quercetin (D+Q): The First-Generation Senolytic

What it is:

Dasatinib — A tyrosine kinase inhibitor (approved for chronic myeloid leukemia) that induces apoptosis in senescent cells via BCL-2 pathway modulation
Quercetin — A natural flavonoid (found in onions, apples, berries) with anti-inflammatory and pro-apoptotic effects

Evidence in humans:

Mayo Clinic (2019): D+Q reduced senescent cell burden in adipose tissue of patients with diabetic kidney disease. Patients showed reductions in circulating SASP factors (IL-6, MMP-9) and improvements in physical function.⁸
Epigenetic aging study (2024): A pilot study found that intermittent D+Q treatment (3-day cycles) was associated with reductions in several DNA methylation clocks (GrimAge, PhenoAge), suggesting potential anti-aging effects.¹⁰
Intervertebral disc degeneration (2021): Long-term D+Q treatment ameliorated age-dependent disc degeneration in mice, reducing senescent cell burden and improving tissue structure.¹¹

Dosing protocols: Most clinics use:

Dasatinib 100 mg + Quercetin 1000 mg once daily for 3 consecutive days
Repeated every 1-3 months

This intermittent “hit-and-run” approach aims to clear senescent cells while minimizing toxicity.

Safety concerns:

Dasatinib can cause thrombocytopenia (low platelets), bleeding risk, and gastrointestinal issues
Not suitable for patients on anticoagulants or with bleeding disorders
Requires baseline labs (complete blood count, liver function) and monitoring

What clinics claim vs. what the data shows:

Some clinics market D+Q as a proven anti-aging intervention. The reality is more nuanced:

Evidence is strongest for reducing senescent cell burden and SASP markers
Functional outcomes (physical performance, metabolic health) show promise in small trials but lack large-scale validation
Long-term safety data are limited
No RCTs have demonstrated extension of lifespan or healthspan in humans

Fisetin: The Natural Senolytic

What it is: A flavonoid found in strawberries, apples, and onions with senolytic properties demonstrated in preclinical studies.

Evidence:

Mouse studies show fisetin can reduce senescent cell burden in aged tissues and extend median lifespan by ~10%¹²
Human data are sparse — mostly small observational studies or anecdotal reports

Dosing:

Clinics typically prescribe 1000-1500 mg/day for 2-3 consecutive days per month

Safety: Generally well-tolerated, but high doses may cause gastrointestinal upset.

Bottom line: Fisetin is marketed as a “natural, safer alternative” to D+Q, but the human evidence is far weaker.

What to Ask Your Longevity Clinic

If you’re considering senolytic therapy, ask:

What biomarkers will you measure?
- Ideally: senescent cell markers (p16, p21, SA-β-gal) in accessible tissues, SASP factors (IL-6, IL-8, MMP-9), inflammatory markers (CRP, TNF-α)
- Reality: Most clinics rely on standard inflammatory panels and epigenetic age clocks, which are indirect measures
What’s the protocol and monitoring plan?
- Frequency of dosing (intermittent is safer than continuous)
- Baseline labs (CBC, liver/kidney function, coagulation)
- Follow-up labs to track response and detect adverse effects
What are the contraindications?
- Bleeding disorders, anticoagulant use, thrombocytopenia
- Active infections or immune compromise (senescent cells play a role in immune function)
Is this part of a comprehensive plan?
- Senolytics work best alongside metabolic optimization, exercise, nutrition, and other longevity interventions
- They’re not a replacement for foundational health behaviors

The Bottlenecks: Why Senolytics Haven’t Delivered Yet

Despite compelling preclinical data, the senolytic field faces major challenges:

1. Lack of Standardized Biomarkers

We still don’t have validated, clinically useful biomarkers to:

Confirm senescent cell clearance
Link cellular changes to functional outcomes
Stratify patients who will benefit most

As Marco Quarta (Rubedo) notes:

“The two biggest hurdles are biomarkers and funding. We lack standardized ways to confirm target engagement and link biological changes to clinical outcomes.”⁹

2. Heterogeneity of Senescent Cells

Senescence is not a single state. Senescent cells in the liver differ from those in the lung, skin, or brain. They express different markers, respond to different stressors, and require different senolytic strategies.

Lorna Harries (SENISCA):

“Our approaches remain very different from the established one-drug-one-indication model. The challenge is that we’re dealing with a multifactorial process that manifests differently across tissues.”⁹

3. Safety and Therapeutic Window

Many first-generation senolytics are repurposed cancer drugs with narrow therapeutic windows. They kill senescent cells — but also healthy cells.

Robin Mansukhani (Deciduous):

“The primary bottleneck is safety. Most senolytic therapies are repurposed cancer drugs with off-target effects, resulting in a very narrow therapeutic window. While this may be acceptable in oncology settings, it is a bottleneck in chronic age-related diseases.”⁹

4. Regulatory Pathways Are Unclear

The FDA doesn’t yet have a clear framework for approving “anti-aging” therapies. Senolytics are being developed for specific indications (fibrosis, AMD, DME), but the field’s ultimate goal — extending healthspan — lacks regulatory precedent.

Lorna Harries:

“Drug regulatory frameworks may require adjustments to fold these new approaches into the mainstream. It’s easy to forget that this is a very new field that requires a regulatory and policy mind shift.”⁹

What to Expect in the Short and Long Term

Short Term (2026-2028):

Proof-of-concept wins in specific diseases — Expect early approvals for senolytics/senomorphics in fibrosis (IPF, liver fibrosis), metabolic disease, and inflammatory conditions where senescence is clearly pathogenic
Better biomarkers — Standardized panels for measuring senescent cell burden and SASP factors will emerge from ongoing trials
Longevity clinics will refine protocols — Expect more evidence-based D+Q protocols with proper monitoring, dosing adjustments, and patient stratification

Long Term (2030+):

Preventive medicine paradigm — Senolytics may shift from treating overt disease to preventing it — similar to how we approach prediabetes or cardiovascular risk today
Multi-modal longevity interventions — Senolytics will be one pillar alongside metabolic optimization (NAD+ boosters, metformin), epigenetic reprogramming, and regenerative medicine
Personalized senolytic selection — Precision medicine will match patients to specific senolytics based on tissue-specific senescent cell profiles

Marco Quarta:

“Senotherapeutics won’t ‘solve’ aging alone; it is a multifactorial process. However, they will be a foundational pillar of longevity medicine alongside metabolic and epigenetic interventions. The goal is to preserve function and resilience for as long as possible.”⁹

The Bottom Line

Senolytics remain one of the most scientifically compelling approaches to longevity medicine — but the field is still in its translational adolescence.

What we know:

Senescent cells drive age-related pathology
Clearing them in mice extends healthspan
D+Q can reduce senescent cell burden in humans

What we don’t know:

Which senolytics work best for which tissues and diseases
How to measure senolytic efficacy in patients
Long-term safety and optimal dosing protocols
Whether senolytic therapy can extend human healthspan or lifespan

If you’re considering senolytic therapy at a longevity clinic:

Choose clinics with physician oversight, baseline labs, and ongoing monitoring — clinics like Progevita, Human Longevity Inc., and Lanserhof integrate senolytic protocols within broader diagnostic frameworks
Understand the evidence gaps — D+Q is promising but not proven in large trials
Treat senolytics as part of a comprehensive longevity strategy, not a standalone biohack
Be wary of clinics making sweeping anti-aging claims without caveats

The next few years will be pivotal. If next-generation senolytics (Rubedo, SENISCA, Deciduous, Arda) show clinical efficacy with acceptable safety, the field could finally deliver on its promise.

Until then, approach with optimism — but grounded in the science, not the hype.

FAQ: Senolytics and Longevity Clinics

Are senolytics FDA-approved?

No. As of March 2026, no senolytic drug has been approved by the FDA. All current clinical use is off-label or experimental.

Is dasatinib + quercetin safe?

D+Q has been tested in small human trials and appears generally safe when used intermittently (3-day cycles every 1-3 months). However, dasatinib can cause low platelets, bleeding risk, and gastrointestinal issues. Not suitable for patients on blood thinners or with bleeding disorders. Always consult a physician.

How do I know if I have high senescent cell burden?

There is no direct consumer test. Some longevity clinics measure inflammatory markers (IL-6, CRP) and epigenetic age clocks as indirect proxies, but these are not senescence-specific.

Can I just take quercetin supplements?

Quercetin alone has weak senolytic activity compared to the D+Q combination. Over-the-counter quercetin doses (500-1000 mg/day) are lower than the high-dose, pulsed protocols used in trials (1000 mg/day for 3 days).

What’s the difference between senolytics and senomorphics?

Senolytics — Kill senescent cells
Senomorphics — Suppress the SASP without killing cells, potentially reducing inflammation while preserving any beneficial functions of senescence

Which longevity clinics offer senolytic therapy?

Several clinics in our directory offer D+Q or fisetin protocols with physician oversight, including Progevita (Valencia, Spain), Human Longevity Inc. (San Diego), Lanserhof (Tegernsee/Sylt, Germany), and Fountain Life (Naples/NYC/Dallas). Look for clinics with baseline labs and evidence-based dosing. See our Best Longevity Clinics 2026 Guide for full comparisons, or use the clinic comparison tool to filter by treatment availability.

When will next-generation senolytics be available?

Rubedo’s RLS-1496, SENISCA’s IPF candidate, and Deciduous’s iNKT modulator are in Phase 1/2 trials. If successful, early approvals could come by 2028-2030, initially for specific diseases (fibrosis, dermatology) before broader healthspan indications.

Baker DJ, et al. (2011). “Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders.” Nature, 479(7372):232-6. PubMed ↩ ↩²
Unity Biotechnology (2023). “UNITY Biotechnology Announces Topline Results from Phase 2 ENVISION Study of UBX1325 in Wet AMD.” Modern Retina. Link ↩
BioSpace (2023). “UNITY Shares Nearly Halved after Lead Asset Fails to Match Regeneron’s Eylea.” Link ↩
Healio (2025). “UBX1325 fails to meet primary analysis endpoint despite vision gains in DME.” Link ↩
Campisi J. (2013). “Aging, cellular senescence, and cancer.” Annual Review of Physiology, 75:685-705. PubMed ↩
Coppé JP, et al. (2010). “Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor.” PLoS Biology, 8(12):e1000301. PubMed ↩
Childs BG, et al. (2015). “Cellular senescence in aging and age-related disease: from mechanisms to therapy.” Nature Medicine, 21(12):1424-35. PubMed ↩
Hickson LJ, et al. (2019). “Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease.” EBioMedicine, 47:446-456. PubMed ↩ ↩²
Lifespan.io (2026). “Cellular Senescence and Senotherapeutics: The Expert Roundup.” Link ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹ ↩¹² ↩¹³ ↩¹⁴
PMC (2024). “Exploring the effects of Dasatinib, Quercetin, and Fisetin on DNA methylation clocks: a longitudinal study on senolytic interventions.” Link ↩
Nature Communications (2021). “Long-term treatment with senolytic drugs Dasatinib and Quercetin ameliorates age-dependent intervertebral disc degeneration in mice.” Link ↩
Yousefzadeh MJ, et al. (2018). “Fisetin is a senotherapeutic that extends health and lifespan.” EBioMedicine, 36:18-28. PubMed ↩